Biography:Mikhail Blagosklonny

From HandWiki
Mikhail Blagosklonny
Alma materFirst Pavlov State Medical University of St. Peterburg
Scientific career
FieldsAnti-aging medicine, oncology
Institutions
  • New York Medical College
  • Roswell Park Comprehensive Cancer Center

Mikhail Blagosklonny is a scientist who studies cancer and aging. He is an adjunct faculty member at Roswell Park Comprehensive Cancer Center in Buffalo, New York.[1]

Career

Blagosklonny earned both his M.D. in internal medicine and his PhD in experimental medicine and cardiology from the First Pavlov State Medical University of St. Petersburg.[citation needed] He was appointed associate professor of medicine at New York Medical College, Valhalla, NY in 2002 before taking a position as a senior scientist at Ordway Research Institute (Albany, New York). Blagosklonny held this position until 2009, when he was appointed professor of oncology at Roswell Park Comprehensive Cancer Center.[2]

Blagosklonny's research interests include cancer and targeted cancer therapies that protect normal cells from damage, as well as the underlying mechanisms of aging (biogerontology) and anti-aging drugs.[3] Roswell Park Comprehensive Cancer Center lists Blagosklonny as holding "Adjunct Faculty" and "Cell Stress Biology" positions with them.[1]

Rapamycin and aging

Blagosklonny has formulated a hypothesis about the possible role of TOR signaling in aging and cancer and proposed using rapamycin, a popular cancer drug as a possible treatment for life extension.[4] He advocates for rapamycin use in longevity research.[5]

Editorial activities

Blagosklonny is editor-in-chief of Aging,[6] Cell Cycle,[7] and Oncotarget.[8] In addition, he is associate editor of Cancer Biology & Therapy[9] and a member of the editorial board of Cell Death & Differentiation.[10]

The peer review process employed by Oncotarget has been criticized by Jeffrey Beall,[11] a university librarian and expert on predatory open access publishing, who also included Oncotarget and Aging on his list of "potential, possible, or probable predatory scholarly open-access journals"[12] in July 2015.[11] Further reports on Beall's blog suggest that the substandard peer review processes for these journals are used by their respective editors-in-chief to entice prospective authors to include references to Blagosklonny's own publications in their articles (following the peer review), thereby raising his personal citation impact.[13]

Health

Blagosklonny announced that in January 2023 he was diagnosed with numerous metastases of lung cancer in his brain.[14]

References

  1. ↑ 1.0 1.1 "About Mikhail Blagosklonny". https://www.roswellpark.org/mikhail-blagosklonny. 
  2. ↑ "Distinguished physician-scientist, Dr. Mikhail Blagosklonny, joins Roswell Park Cancer Institute", Cancer Biology & Therapy 8 (9): 753–752, May 2009, doi:10.4161/cbt.8.9.8899 
  3. ↑ "Distinguished physician-scientist, Dr. Mikhail Blagosklonny, joins Roswell Park Cancer Institute". Cancer Biology & Therapy 8 (9): 753–752. May 2009. doi:10.4161/cbt.8.9.8899. 
  4. ↑ Stipp, David (2011). "A New Path to Longevity". Scientific American 306 (1): 32–39. doi:10.1038/scientificamerican0112-32. PMID 22279832. Bibcode: 2011SciAm.306f..32S. 
  5. ↑ "Does a Real Anti-Aging Pill Already Exist? Inside Novartis's push to produce the first legitimate anti-aging drug, Business Week, 2015". Bloomberg.com. 12 February 2015. https://www.bloomberg.com/news/features/2015-02-12/does-a-real-anti-aging-pill-already-exist-. Retrieved November 20, 2016. 
  6. ↑ "Editorial Board". Aging. http://www.impactaging.com/editors.html. Retrieved 2016-11-20. 
  7. ↑ "Editorial Board". Cell Cycle. Taylor & Francis. http://www.tandfonline.com/action/journalInformation?show=editorialBoard&journalCode=kccy20. Retrieved 2016-11-20. 
  8. ↑ "Editorial Board". Oncotarget. http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=pages&op=view&path%5B%5D=board. Retrieved 2016-11-20. 
  9. ↑ "Editorial board". Cancer Biology & Therapy. Taylor & Francis. http://www.tandfonline.com/action/journalInformation?show=editorialBoard&journalCode=kcbt20. Retrieved 2016-11-20. 
  10. ↑ "About the journal". Cell Death & Differentiation. http://www.nature.com/cdd/about.html. Retrieved 2016-11-20. 
  11. ↑ 11.0 11.1 Beall, Jeffrey (19 April 2016). "Oncotarget's Peer Review is Highly Questionable". Archived from the original on 20 April 2016. https://web.archive.org/web/20160420235706/https://scholarlyoa.com/2016/04/19/oncotargets-peer-review-is-highly-questionable/. Retrieved 2016-11-20. 
  12. ↑ Beall, Jeffrey (2016-11-20). "LIST OF STANDALONE JOURNALS: Potential, possible, or probable predatory scholarly open-access journals". Archived from the original on 2 December 2016. https://web.archive.org/web/20161202192038/https://scholarlyoa.com/individual-journals/. Retrieved 19 April 2016. 
  13. ↑ "Mikhail Blagosklonny's Journal Aging: A Review". 6 December 2016. Archived from the original on 24 December 2016. https://web.archive.org/web/20161224004259/https://scholarlyoa.com/2016/12/06/mikhail-blagosklonnys-journal-aging-a-review/. Retrieved 17 January 2017. 
  14. ↑ "My battle with cancer". 26 October 2023. https://www.mikhailblagosklonny.com/blog/my-battle-with-cancer/. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Biography:Mikhail_Blagosklonny&oldid=3404764"